Wanbangde Pharmaceutical Holding Group Co., Ltd. Stock

Equities

002082

CNE000001P94

Pharmaceuticals

End-of-day quote Shenzhen S.E. 06:00:00 2024-05-09 pm EDT 5-day change 1st Jan Change
5.18 CNY -2.45% Intraday chart for Wanbangde Pharmaceutical Holding Group Co., Ltd. +4.65% -19.06%
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Days!
Take advantage of the offer
* See conditions on site
Sales 2022 1.79B 247M Sales 2023 1.54B 213M Capitalization 3.91B 542M
Net income 2022 93M 12.87M Net income 2023 49M 6.78M EV / Sales 2022 3.25 x
Net Debt 2022 397M 54.93M Net Debt 2023 749M 104M EV / Sales 2023 3.02 x
P/E ratio 2022
58.8 x
P/E ratio 2023
80 x
Employees 1,569
Yield 2022
1.36%
Yield 2023
1.25%
Free-Float 44.52%
More Fundamentals * Assessed data
Dynamic Chart
US FDA Gives Rare Pediatric Disease Drug Designation to Wanbangde Pharmaceutical's Huperzine A MT
Wanbangde Pharmaceutical Holding Group Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Wanbangde Pharmaceutical Holding Group Co., Ltd. Proposes Final Cash Dividend for the Year 2023 CI
Wanbangde Pharmaceutical Holding Group Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Wanbangde Pharma Elects Vice Chairman, Appoints CFO MT
Wanbangde Pharma's Anesthesia Passes Drug Regulator's Consistency Evaluation MT
Wanbangde Pharmaceutical Holding Group Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023 CI
Wanbangde Pharmaceutical Holding Group Co., Ltd.(XSEC:002082) added to S&P Global BMI Index CI
Wanbangde Pharmaceutical Holding Group Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023 CI
Wanbangde Pharmaceutical Holding Group Co., Ltd. Approves Board Appointments CI
Wanbangde Pharmaceutical Registers New Medical Device MT
Wanbangde Pharmaceutical Holding Group Co., Ltd. Announces Final Cash Dividend on A Shares for the Year 2022, Payable on 05 June 2023 CI
Wanbangde Pharmaceutical Holding Group Co., Ltd. Approves Cash Dividend for the Year 2022 CI
Wanbangde Pharmaceutical Holding Group Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
Wanbangde Pharmaceutical Holding Group Co., Ltd. Announces Final Profit Distribution Proposal for 2022 CI
More news
1 day-2.45%
1 week+4.65%
Current month+4.65%
1 month+3.39%
3 months+22.17%
6 months-22.34%
Current year-19.06%
More quotes
1 week
5.01
Extreme 5.01
5.36
1 month
4.07
Extreme 4.07
5.36
Current year
3.70
Extreme 3.7
6.65
1 year
3.70
Extreme 3.7
7.97
3 years
3.70
Extreme 3.7
17.35
5 years
3.70
Extreme 3.7
17.67
10 years
3.70
Extreme 3.7
28.89
More quotes
Managers TitleAgeSince
Chief Executive Officer 60 17-07-13
Director/Board Member 59 17-07-13
Investor Relations Contact - -
Members of the board TitleAgeSince
Chairman 75 17-07-13
Chief Executive Officer 60 17-07-13
Director/Board Member 59 17-07-13
More insiders
Date Price Change Volume
24-05-10 5.18 -2.45% 6,068,959
24-05-09 5.31 +1.14% 6,904,111
24-05-08 5.25 +2.14% 9,090,739
24-05-07 5.14 0.00% 6,678,639

End-of-day quote Shenzhen S.E., May 09, 2024

More quotes
Wepon Pharmaceutical Holding Group Co Ltd, formerly Wanbangde Pharmaceutical Holding Group Co Ltd, is a China-based company mainly engaged in the manufacture of pharmaceuticals and medical devices. The Company primarily operates through three segments. The Pharmaceutical Manufacturing segment is mainly engaged in the research and development, production and sales of modern Chinese medicines, chemical raw materials and chemical preparations. The Medical Device segment is mainly engaged in the research and development of medical devices, medical equipment services and provision of hospital engineering services. The Company also conducts its business through the Other segment. The Company conducts its business in the domestic and overseas markets.
Calendar
More about the company
  1. Stock Market
  2. Equities
  3. 002082 Stock
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW